Do analysts rate RDY or ALMS?

Alumis has a consensus target price of $40.30, indicating a potential upside of 51.28%. Given Alumis' stronger consensus rating and higher probable upside, analysts clearly believe Alumis is more favorable than Dr. Reddy's Laboratories. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dr. Reddy's Laboratories 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Alumis 1 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.83

Does the media refer more to RDY or ALMS?

In the previous week, Dr. Reddy's Laboratories and Dr. Reddy's Laboratories both had 2 articles in the media. Alumis' average media sentiment score of 0.94 beat Dr. Reddy's Laboratories' score of -0.23 indicating that Alumis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dr. Reddy's Laboratories 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Alumis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, AXSM or ALMS?

Axsome Therapeutics has higher revenue and earnings than Alumis. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Alumis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Axsome Therapeutics $638.50M 19.40 -$183.17M -$3.73 N/A Alumis $24.05M 141.22 -$243.32M -$1.98 N/A

Is AXSM or ALMS more profitable?

Axsome Therapeutics has a net margin of -26.59% compared to Alumis' net margin of -2,825.70%. Alumis' return on equity of -88.79% beat Axsome Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Axsome Therapeutics -26.59% -267.16% -28.53% Alumis -2,825.70% -88.79% -70.72%

Does the media favor AXSM or ALMS?

In the previous week, Axsome Therapeutics had 5 more articles in the media than Alumis. MarketBeat recorded 7 mentions for Axsome Therapeutics and 2 mentions for Alumis. Alumis' average media sentiment score of 0.94 beat Axsome Therapeutics' score of 0.77 indicating that Alumis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Alumis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ALMS or ELAN?

In the previous week, Elanco Animal Health had 2 more articles in the media than Alumis. MarketBeat recorded 4 mentions for Elanco Animal Health and 2 mentions for Alumis. Elanco Animal Health's average media sentiment score of 1.13 beat Alumis' score of 0.94 indicating that Elanco Animal Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alumis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Elanco Animal Health 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ARWR or ALMS?

In the previous week, Arrowhead Pharmaceuticals had 11 more articles in the media than Alumis. MarketBeat recorded 13 mentions for Arrowhead Pharmaceuticals and 2 mentions for Alumis. Arrowhead Pharmaceuticals' average media sentiment score of 0.99 beat Alumis' score of 0.94 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arrowhead Pharmaceuticals 4 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alumis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ALMS or SMMT more profitable?

Summit Therapeutics has a net margin of 0.00% compared to Alumis' net margin of -2,825.70%. Alumis' return on equity of -88.79% beat Summit Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Alumis -2,825.70% -88.79% -70.72% Summit Therapeutics N/A -291.24% -243.07%

Does the media refer more to ALMS or SMMT?

In the previous week, Alumis and Alumis both had 2 articles in the media. Summit Therapeutics' average media sentiment score of 1.81 beat Alumis' score of 0.94 indicating that Summit Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alumis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Summit Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Alumis (ALMS) Competitors

$26.64 -1.50 (-5.33%)

Closing price 07/1/2026 04:00 PM Eastern

Extended Trading

$26.64 +0.00 (+0.02%)

As of 07/1/2026 07:44 PM Eastern

Compare

ALMS vs. RDY, AXSM, ELAN, ARWR, and SMMT

Should you buy Alumis stock or one of its competitors? MarketBeat compares Alumis with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Alumis include Dr. Reddy's Laboratories (RDY), Axsome Therapeutics (AXSM), Elanco Animal Health (ELAN), Arrowhead Pharmaceuticals (ARWR), and Summit Therapeutics (SMMT). These companies are all part of the "pharmaceutical products" industry.

How does Alumis compare to Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories (NYSE:RDY) and Alumis (NASDAQ:ALMS) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, risk, valuation, profitability and analyst recommendations.

Dr. Reddy's Laboratories has a beta of 0.25, suggesting that its share price is 75% less volatile than the broader market. Comparatively, Alumis has a beta of -0.74, suggesting that its share price is 174% less volatile than the broader market.

Dr. Reddy's Laboratories has a net margin of 12.90% compared to Alumis' net margin of -2,825.70%. Dr. Reddy's Laboratories' return on equity of 12.34% beat Alumis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dr. Reddy's Laboratories	12.90%	12.34%	8.24%
Alumis	-2,825.70%	-88.79%	-70.72%

Dr. Reddy's Laboratories has higher revenue and earnings than Alumis. Alumis is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dr. Reddy's Laboratories	$3.58B	3.27	$456M	$0.58	24.21
Alumis	$24.05M	141.22	-$243.32M	-$1.98	N/A

In the previous week, Dr. Reddy's Laboratories and Dr. Reddy's Laboratories both had 2 articles in the media. Alumis' average media sentiment score of 0.94 beat Dr. Reddy's Laboratories' score of -0.23 indicating that Alumis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dr. Reddy's Laboratories	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alumis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alumis has a consensus target price of $40.30, indicating a potential upside of 51.28%. Given Alumis' stronger consensus rating and higher probable upside, analysts clearly believe Alumis is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dr. Reddy's Laboratories	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Alumis	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

3.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are owned by company insiders. Comparatively, 33.7% of Alumis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Dr. Reddy's Laboratories beats Alumis on 9 of the 16 factors compared between the two stocks.

How does Alumis compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and Alumis (NASDAQ:ALMS) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

Axsome Therapeutics has higher revenue and earnings than Alumis. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Alumis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$638.50M	19.40	-$183.17M	-$3.73	N/A
Alumis	$24.05M	141.22	-$243.32M	-$1.98	N/A

81.5% of Axsome Therapeutics shares are owned by institutional investors. 20.6% of Axsome Therapeutics shares are owned by company insiders. Comparatively, 33.7% of Alumis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Axsome Therapeutics has a beta of 0.6, indicating that its stock price is 40% less volatile than the broader market. Comparatively, Alumis has a beta of -0.74, indicating that its stock price is 174% less volatile than the broader market.

Axsome Therapeutics currently has a consensus price target of $258.95, suggesting a potential upside of 7.60%. Alumis has a consensus price target of $40.30, suggesting a potential upside of 51.28%. Given Alumis' higher probable upside, analysts plainly believe Alumis is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	0 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.95
Alumis	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

Axsome Therapeutics has a net margin of -26.59% compared to Alumis' net margin of -2,825.70%. Alumis' return on equity of -88.79% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-26.59%	-267.16%	-28.53%
Alumis	-2,825.70%	-88.79%	-70.72%

In the previous week, Axsome Therapeutics had 5 more articles in the media than Alumis. MarketBeat recorded 7 mentions for Axsome Therapeutics and 2 mentions for Alumis. Alumis' average media sentiment score of 0.94 beat Axsome Therapeutics' score of 0.77 indicating that Alumis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Alumis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Axsome Therapeutics beats Alumis on 9 of the 16 factors compared between the two stocks.

How does Alumis compare to Elanco Animal Health?

Alumis (NASDAQ:ALMS) and Elanco Animal Health (NYSE:ELAN) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, earnings, risk, profitability and media sentiment.

In the previous week, Elanco Animal Health had 2 more articles in the media than Alumis. MarketBeat recorded 4 mentions for Elanco Animal Health and 2 mentions for Alumis. Elanco Animal Health's average media sentiment score of 1.13 beat Alumis' score of 0.94 indicating that Elanco Animal Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alumis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Elanco Animal Health	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Elanco Animal Health has higher revenue and earnings than Alumis. Elanco Animal Health is trading at a lower price-to-earnings ratio than Alumis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alumis	$24.05M	141.22	-$243.32M	-$1.98	N/A
Elanco Animal Health	$4.72B	2.55	-$232M	-$0.50	N/A

Alumis currently has a consensus target price of $40.30, indicating a potential upside of 51.28%. Elanco Animal Health has a consensus target price of $28.55, indicating a potential upside of 18.57%. Given Alumis' stronger consensus rating and higher possible upside, research analysts plainly believe Alumis is more favorable than Elanco Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alumis	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

97.5% of Elanco Animal Health shares are owned by institutional investors. 33.7% of Alumis shares are owned by insiders. Comparatively, 1.1% of Elanco Animal Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Alumis has a beta of -0.74, indicating that its share price is 174% less volatile than the broader market. Comparatively, Elanco Animal Health has a beta of 1.68, indicating that its share price is 68% more volatile than the broader market.

Elanco Animal Health has a net margin of -4.95% compared to Alumis' net margin of -2,825.70%. Elanco Animal Health's return on equity of 7.42% beat Alumis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alumis	-2,825.70%	-88.79%	-70.72%
Elanco Animal Health	-4.95%	7.42%	3.66%

Summary

Elanco Animal Health beats Alumis on 10 of the 15 factors compared between the two stocks.

How does Alumis compare to Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Alumis (NASDAQ:ALMS) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, media sentiment, earnings, analyst recommendations, profitability and risk.

Arrowhead Pharmaceuticals presently has a consensus target price of $87.27, suggesting a potential upside of 8.49%. Alumis has a consensus target price of $40.30, suggesting a potential upside of 51.28%. Given Alumis' stronger consensus rating and higher possible upside, analysts plainly believe Alumis is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69
Alumis	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

Arrowhead Pharmaceuticals has a beta of 1.26, suggesting that its share price is 26% more volatile than the broader market. Comparatively, Alumis has a beta of -0.74, suggesting that its share price is 174% less volatile than the broader market.

Arrowhead Pharmaceuticals has a net margin of -48.38% compared to Alumis' net margin of -2,825.70%. Arrowhead Pharmaceuticals' return on equity of -55.09% beat Alumis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arrowhead Pharmaceuticals	-48.38%	-55.09%	-18.13%
Alumis	-2,825.70%	-88.79%	-70.72%

62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. 3.6% of Arrowhead Pharmaceuticals shares are held by company insiders. Comparatively, 33.7% of Alumis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Arrowhead Pharmaceuticals had 11 more articles in the media than Alumis. MarketBeat recorded 13 mentions for Arrowhead Pharmaceuticals and 2 mentions for Alumis. Arrowhead Pharmaceuticals' average media sentiment score of 0.99 beat Alumis' score of 0.94 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arrowhead Pharmaceuticals	4 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alumis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Arrowhead Pharmaceuticals has higher revenue and earnings than Alumis. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Alumis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arrowhead Pharmaceuticals	$829.45M	13.66	-$1.63M	-$2.15	N/A
Alumis	$24.05M	141.22	-$243.32M	-$1.98	N/A

Summary

Arrowhead Pharmaceuticals beats Alumis on 9 of the 16 factors compared between the two stocks.

How does Alumis compare to Summit Therapeutics?

Alumis (NASDAQ:ALMS) and Summit Therapeutics (NASDAQ:SMMT) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Summit Therapeutics has a net margin of 0.00% compared to Alumis' net margin of -2,825.70%. Alumis' return on equity of -88.79% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alumis	-2,825.70%	-88.79%	-70.72%
Summit Therapeutics	N/A	-291.24%	-243.07%

In the previous week, Alumis and Alumis both had 2 articles in the media. Summit Therapeutics' average media sentiment score of 1.81 beat Alumis' score of 0.94 indicating that Summit Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alumis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Summit Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Alumis presently has a consensus price target of $40.30, indicating a potential upside of 51.28%. Summit Therapeutics has a consensus price target of $26.97, indicating a potential upside of 87.57%. Given Summit Therapeutics' higher probable upside, analysts clearly believe Summit Therapeutics is more favorable than Alumis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alumis	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
Summit Therapeutics	2 Sell rating(s)	6 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.44

Alumis has higher revenue and earnings than Summit Therapeutics. Alumis is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alumis	$24.05M	141.22	-$243.32M	-$1.98	N/A
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.60	N/A

4.6% of Summit Therapeutics shares are owned by institutional investors. 33.7% of Alumis shares are owned by insiders. Comparatively, 83.5% of Summit Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Alumis has a beta of -0.74, suggesting that its share price is 174% less volatile than the broader market. Comparatively, Summit Therapeutics has a beta of -1.26, suggesting that its share price is 226% less volatile than the broader market.

Summary

Alumis and Summit Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

Get Alumis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALMS vs. The Competition

Export

Metric	Alumis	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.59B	$3.67B	$6.79B	$12.59B
Dividend Yield	N/A	2.21%	2.66%	6.15%
P/E Ratio	-13.45	21.28	27.67	25.27
Price / Sales	141.22	324.37	533.25	101.18
Price / Cash	N/A	141.54	47.99	59.26
Price / Book	9.25	8.71	10.96	6.62
Net Income	-$243.32M	$23.87M	$3.57B	$336.83M
7 Day Performance	6.43%	4.34%	2.88%	3.19%
1 Month Performance	32.93%	6.62%	3.69%	0.86%
1 Year Performance	712.20%	61.64%	34.39%	27.51%

Alumis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALMS Alumis	3.1432 of 5 stars	$26.64 -5.3%	$40.30 +51.3%	+782.1%	$3.59B	$24.05M	N/A	N/A
RDY Dr. Reddy's Laboratories	1.7035 of 5 stars	$15.39 +0.9%	N/A	-6.0%	$12.73B	$3.58B	26.53	27,527
AXSM Axsome Therapeutics	2.0901 of 5 stars	$242.15 +2.0%	$258.95 +6.9%	+133.7%	$12.21B	$638.50M	N/A	380	Insider Trade High Trading Volume
ELAN Elanco Animal Health	3.9158 of 5 stars	$24.56 +0.8%	$28.55 +16.2%	+66.7%	$12.17B	$4.72B	N/A	9,400	Positive News Analyst Forecast
ARWR Arrowhead Pharmaceuticals	2.2902 of 5 stars	$78.89 -0.5%	$86.36 +9.5%	+399.9%	$11.17B	$829.45M	N/A	400	News Coverage Analyst Forecast High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALMS) was last updated on 7/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alumis (ALMS) Competitors

ALMS vs. RDY, AXSM, ELAN, ARWR, and SMMT

How does Alumis compare to Dr. Reddy's Laboratories?

Summary

How does Alumis compare to Axsome Therapeutics?

Summary

How does Alumis compare to Elanco Animal Health?

Summary

How does Alumis compare to Arrowhead Pharmaceuticals?

Summary

How does Alumis compare to Summit Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALMS vs. The Competition

Alumis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alumis (ALMS) Competitors

ALMS vs. RDY, AXSM, ELAN, ARWR, and SMMT

How does Alumis compare to Dr. Reddy's Laboratories?

Which has more risk & volatility, RDY or ALMS?

Is RDY or ALMS more profitable?

Which has better earnings & valuation, RDY or ALMS?

Does the media refer more to RDY or ALMS?

Do analysts rate RDY or ALMS?

Do institutionals & insiders have more ownership in RDY or ALMS?

Summary

How does Alumis compare to Axsome Therapeutics?

Which has better valuation and earnings, AXSM or ALMS?

Do insiders and institutionals hold more shares of AXSM or ALMS?

Which has more volatility and risk, AXSM or ALMS?

Do analysts rate AXSM or ALMS?

Is AXSM or ALMS more profitable?

Does the media favor AXSM or ALMS?

Summary

How does Alumis compare to Elanco Animal Health?

Does the media refer more to ALMS or ELAN?

Which has stronger earnings and valuation, ALMS or ELAN?

Do analysts prefer ALMS or ELAN?

Do insiders and institutionals have more ownership in ALMS or ELAN?

Which has more risk & volatility, ALMS or ELAN?

Is ALMS or ELAN more profitable?

Summary

How does Alumis compare to Arrowhead Pharmaceuticals?

Do analysts prefer ARWR or ALMS?

Which has more risk and volatility, ARWR or ALMS?

Is ARWR or ALMS more profitable?

Do insiders & institutionals have more ownership in ARWR or ALMS?

Does the media favor ARWR or ALMS?

Which has stronger valuation & earnings, ARWR or ALMS?

Summary

How does Alumis compare to Summit Therapeutics?

Is ALMS or SMMT more profitable?

Does the media refer more to ALMS or SMMT?

Do analysts recommend ALMS or SMMT?

Which has better valuation & earnings, ALMS or SMMT?

Do insiders and institutionals believe in ALMS or SMMT?

Which has more volatility & risk, ALMS or SMMT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALMS vs. The Competition

Alumis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools